Company: Mirati Therapeutics Inc.
Job title: Medical Affairs Strategy GI Lead
Targeting KRAS Mutant Colorectal Cancer with a KRAS G12C Inhibitor: Current Status and Future Questions 10:30 am
History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C in CRC Clinical progress of KRAS G12C inhibitors (e.g. adagrasib) and treatment of patients with KRAS G12C mutated CRC Future questions and directions for targeting KRAS G12C in CRC, including combination strategiesRead more
day: Day One